Search Results

Analysts tentatively welcomed Novo’s new corporate rebrand—so long as it comes with a larger change to the company’s overall business strategy.

ContraFect Corporation announces business updates and financial results for the second quarter ended June 30, 2023.

Corporate Treasury Positioned with Cash and Liquid Equity Holdings to Seed, Incubate and Accelerate New and Existing Operations

ContraFect Corporation announced financial results and business updates for the third quarter ended September 30, 2022.

ContraFect Corporation today announces that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on September 15, 2023.

ContraFect Corporation (Nasdaq: CFRX) today announces business updates and financial results for the first quarter ended March 31, 2023.

ContraFect Corporation today announces that Jane Ambler, Ph.D., the Company’s Vice President of Clinical Microbiology, will be presenting at the ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, which will be held in Boston.

ContraFect Corporation announces that Garrett Nichols, M.D., M.S., the Company’s Interim Chief Medical Officer, will be presenting an updated overview of the Company’s DLA programs that target antibiotic-resistant pathogens at the World Anti-Microbial Congress 2023, which will be held in Philadelphia, PA from September 7-8, 2023.